Navigation Links
Neurocrine Biosciences Reports Second Quarter 2014 Results
Date:8/6/2014

hare-based compensation expense.

General and administrative expenses increased from $3.4 million for the second quarter of 2013 to $4.2 million for the second quarter of 2014.  For the six months ended June 30, 2014 general and administrative expenses were $8.4 million, compared to $6.8 million for the first half of 2013.  The increase in general and administrative expense is primarily due to higher share-based compensation expense.

Pipeline HighlightsVMAT2 UpdateThe Company recently held an End-of-Phase II meeting with the FDA for its VMAT2 inhibitor, NBI-98854.  The FDA reviewed the current data package and clinical development plan for NBI-98854 and commented on the overall proposal for Phase III development to support the registration of NBI-98854 in the United States as a treatment for tardive dyskinesia.  Based on the results of this meeting and the related minutes, the Company will conduct a single placebo-controlled Phase III study of NBI-98854, the Kinect 3 study. The Kinect 3 study, along with the previous efficacy studies of NBI-98854, will complete the placebo-controlled clinical efficacy evaluation of NBI-98854 in tardive dyskinesia. The primary endpoint in the Kinect 3 study will be the mean change from baseline in the Abnormal Involuntary Movement Scale (AIMS) as assessed by blinded central raters.  The Kinect 3 study will include approximately 240 subjects randomized to either placebo, once daily 40mg of NBI-98854 or once daily 80mg of NBI-98854 for 6 weeks of placebo-controlled dosing followed by an extension of active dosing through Week 48.  The Company also intends to conduct a separate one-year open-label safety study of NBI-98854 to support the anticipated 2016 filing of a New Drug Application in tardive dyskinesia.

The Company is also expecting to submit an Investigational New Drug application for NBI-98854 in Tourette syndrome later this month and plans to commence the clinical progr
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet guide ... that is helping people learn the truth about so-called health ... in less than 24 hours has caught the attention of ... culture that is becoming so obsessed with diets and weight ... fact and fiction when it comes to health foods, eating ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... 30, 2014 Two revolutionary procedures now being ... of gum disease a far less painful and far ... “If you’ve ever felt electric shock waves surge through your ... cold beverage, it’s possible you already know the impact of ... a general dentist in West Palm Beach, and a Fellow ...
(Date:9/30/2014)... An unprecedented, public-private partnership funded by the Department ... the development of better-run clinical trials and may ... brain injury, a condition affecting not only athletes ... public, ranging from youngsters to elders. , ... with a $17 million, five-year award from the ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Healthpointe ... is now performing advanced foot and ankle reconstruction surgeries ... board-certified orthopedic surgeon, Dr. Cortés specializes in the diagnosis ... ankle injuries . She is also trained to perform ... their orthopedic needs. Dr. Cortés is also fluent in ...
Breaking Medicine News(10 mins):Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3
... Applications in Healthcare (C-PAHC) Now Accepting ... ... Records Institute introduces,today the Center for Cell Phone Applications in Healthcare ... phone applications in healthcare., (Logo: http://www.newscom.com/cgi-bin/prnh/20080825/NEM092LOGO ), ...
... best available option for people with hemochromatosis , , ... dismissed as a primitive form of medicine, in which ... humors by draining the life-sustaining fluid. , But there,s ... the preferred means of treatment. , Hemochromatosis is an ...
... invivodata to 2008 Pittsburgh 100, PITTSBURGH, Aug. ... patient reported outcomes (ePRO) solutions and,services for global ... has recognized the company in the "2008 Pittsburgh ... Western,Pennsylvania., "We see the Pittsburgh 100 as ...
... avoidance strategies , , MONDAY, Aug. 25 (HealthDay News) -- ... to ensure the safety of the more than 2.2 ... Academy of Allergy, Asthma & Immunology. , "Open and ... key ingredient to keeping food-allergic students out of harm. ...
... YORK, Aug. 25 HMS Holdings Corp. (Nasdaq:,HMSY) today ... Partners,2008 Healthcare Conference, which will be held September 3-5, ... Walter Hosp, SVP and Chief Financial Officer of HMS ... pm Eastern Time., A live broadcast of the ...
... 25 Dr. Anthony Ohotto, a physician,with Signature Hospice, ... "Limited life expectancy is no reason not to do ... the order as a health clearance, a,statement that the ... The Hospice team members at Signature Hospice had noted ...
Cached Medicine News:Health News:Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:invivodata Recognized as One of Pittsburgh's Fastest Growing Private Companies 2Health News:Food Allergy Action Plan Can Keep Kids From Harm 2Health News:Signature Hospice Team Grants Patient's Unusual Wish 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with 15 mm long jaws. Serrated handle with polished finish. Smooth jaws....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Medicine Products: